1. Home
  2. HKIT vs BYSI Comparison

HKIT vs BYSI Comparison

Compare HKIT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

HOLD

Current Price

$2.44

Market Cap

28.3M

Sector

Technology

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.76

Market Cap

31.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKIT
BYSI
Founded
1996
2010
Country
China
United States
Employees
N/A
44
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.3M
31.4M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
HKIT
BYSI
Price
$2.44
$0.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.8K
2.0M
Earning Date
04-24-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.57
52 Week High
$8.80
$2.44

Technical Indicators

Market Signals
Indicator
HKIT
BYSI
Relative Strength Index (RSI) 38.72 48.14
Support Level $2.36 $0.67
Resistance Level $2.59 $1.25
Average True Range (ATR) 0.21 0.06
MACD -0.06 0.03
Stochastic Oscillator 8.26 86.45

Price Performance

Historical Comparison
HKIT
BYSI

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: